Vowst is indicated for preventing the recurrence of C difficile infection. Credit: Nephron / commons.wikimedia.org.

and Nestl茅 Health Science have from the US Food and Drug Administration (FDA) for Vowst (faecal microbiota spores, live-brpk) for preventing the recurrence of C difficile infection (CDI) in adults.

Vowst is an orally administered microbiota-based therapeutic, previously known as SER-109, and is indicated for the prevention of recurrence of CDI in people aged 18 years and above following an antibacterial treatment for recurrent CDI (rCDI). It is not indicated to treat CDI.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The regulator had previously granted breakthrough therapy and orphan drug designations to Vowst.

Seres president and CEO Eric Shaff said: 鈥淪eres has led the development of microbiome therapeutics, and today鈥檚 FDA approval of Vowst as the first orally administered microbiota-based therapeutic for the prevention of recurrent C difficile infection marks a tremendous milestone for the patient community, and for Seres.

鈥淲e are deeply grateful to the patients, caregivers, clinical investigators and employees who contributed to the discovery, development and approval of Vowst.

鈥淲ith Vowst, we and Nestl茅 Health Science have the opportunity to prevent recurrence in a broad group of adult rCDI patients, including those who have experienced a first recurrence.鈥�

The regulatory approval was supported by a Phase III development programme which included the ECOSPOR III and ECOSPOR IV trials.

The primary objective of the randomised placebo controlled, multi-centre ECOSPOR III trial was to show a reduction of CDI recurrence in individuals with rCDI.

Vowst reduced CDI recurrence, with 88% of participants recurrence-free eight weeks after receiving treatment compared to 60% of those administered a placebo.

Seres and Nestl茅 Health Science signed an agreement in July 2021 to work together for the commercialisation of Vowst in Canada and the US.